Key result
Amiodarone provides favorable net clinical benefit for atrial fibrillation management, but less favorable benefit for sudden cardiac death prophylaxis (NNT 38 vs NNH 14; p<0.001).
Why the study?
Does amiodarone improve arrhythmia outcomes at the cost of increased adverse effects compared to placebo in patients with cardiac tachyarrhythmias?
Systematic Review
Does amiodarone improve arrhythmia outcomes at the cost of increased adverse effects compared to placebo in patients with cardiac tachyarrhythmias?
Amiodarone provides a favorable net clinical benefit for atrial fibrillation management but has a less favorable risk-benefit profile for sudden cardiac death prophylaxis due to significant organ toxicity.
No takes yet. Share an insight, caveat, or question.
Supports amiodarone for AF but cautions against SCD prophylaxis; confirms differential net benefit and refines risk stratification.
Santangeli et al. (2012) conducted a systematic review in Cardiac tachyarrhythmias. Amiodarone vs. Placebo was evaluated on Number needed to treat (NNT) and number needed to harm (NNH). Amiodarone provides favorable net clinical benefit for atrial fibrillation management, but less favorable benefit for sudden cardiac death prophylaxis (NNT 38 vs NNH 14; p<0.001).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: